Addex Therapeutics

Cash was CHF 0.94 million at March 31, 2026. Q1 2026 net loss was CHF 1.71 million. 2025 operating cash outflow was CHF 2.17 million. Auditors and management highlight substantial doubt about going concern. While debt is minimal, equity financing at this stage is likely dilutive.

The 20% stake in Neurosterix is non‑liquid and was marked down by share of loss in Q1 2026, limiting near‑term funding options.